Clinical application of recombinant human bone morphogenetic protein in cats and dogs: A review of 13 cases

Databases (2001-2008) for cases in which recombinant bone morphogenetic protein (rhBMP) was used to aid in management of orthopedic disease were reviewed and cases were categorized as non-unions, delayed unions, and cases expected to heal with difficulty. If follow-up in the medical record was < 6 mo for live animals, owners were surveyed by telephone. Thirteen cases (11 dogs, 2 cats) were identified; OP-1 (rhBMP-7) was used in 3 cases and INFUSE (rhBMP-2) in 10. Mean time from injury to rhBMP use for non- and delayed union cases was 156 d; mean time from rhBMP use to radiographic healing was 101 d. No systemic side effects were reported. All patients achieved clinical and radiographic bone union following rhBMP administration. Recombinant human BMP was used in 13 veterinary patients to successfully achieve bone union without serious deleterious effects in a variety of clinical applications.